AL01211 is a novel selective oral glucoceramine synthase GCS inhibitor. AceLink has completed two Phase I clinical trials of AL01211 in healthy subjects in Australia and China. Both studies showed that AL01211 was safe and well tolerated, with no serious adverse reactions observed at any trial dose level. Currently, the drug is undergoing Phase II clinical trials in patients with Fabry disease in China and the United States.
About
Tekoro Tekoro Biotech Chengdu Co., Ltd., located in Tianfu International Bio-City, Chengdu, Sichuan, China, is a clinical-stage biopharmaceutical company focused on developing innovative therapies for androgenic alopecia, atopic dermatitis, psoriasis, systemic lupus erythematosus, and scar clearance. The company's core pipeline includes TDM-105795 sri lanka telegram data for androgenic alopecia and TDM-180935 for atopic dermatitis. The two projects, TDM-105795 and TDM-180935, have obtained preliminary efficacy verification in Phase IIa trials, showing good development prospects. The company expects to advance another innovative small molecule oral drug into Phase I clinical research in 2025 to examine the drug's safety and pharmacokinetic properties, and subsequently use the drug to treat rare skin diseases and other immune-related inflammatory skin diseases. Tekoro's R&D pipeline focuses on the development of drugs for skin diseases.
Vivo Biopharmaceuticals is a clinical-stage innovative pharmaceutical company focused on ophthalmic therapeutics. The company is formed by a world-class team of ophthalmic drug research and development experts and has established a unique ophthalmic innovative drug research and development platform. Many of its independently developed innovative drug products have entered or are about to enter the clinical stage. For more information, visit: ivavisionbio .